Shareholders in Bio-Rad Laboratories (NYSE:BIO) Are in the Red If They Invested Three Years Ago
Shareholders in Bio-Rad Laboratories (NYSE:BIO) Are in the Red If They Invested Three Years Ago
The truth is that if you invest for long enough, you're going to end up with some losing stocks. But the long term shareholders of Bio-Rad Laboratories, Inc. (NYSE:BIO) have had an unfortunate run in the last three years. Unfortunately, they have held through a 57% decline in the share price in that time. And more recent buyers are having a tough time too, with a drop of 28% in the last year.
事實上,如果你投資足夠長的時間,最終一定會遇到賠錢股票。但長揸Bio-Rad Laboratories, Inc.(紐交所:BIO)的股東在過去的三年中的確經歷了不幸的遭遇。在那段時間裏,股價下跌了57%。更近期的購買者也遭遇了困難,去年股價下跌了28%。
It's worthwhile assessing if the company's economics have been moving in lockstep with these underwhelming shareholder returns, or if there is some disparity between the two. So let's do just that.
值得評估公司的經濟狀況是否與這些不盡如人意的股東回報同時發展並步調一致,或者兩者之間是否存在差異。因此,讓我們來看看。
There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.
市場有時毫無疑問是有效的,但股票價格並不總是反映基本業務表現。一種有缺陷但合理的方法是比較每股收益(EPS)和股票價格,以評估圍繞公司的情緒如何變化。
We know that Bio-Rad Laboratories has been profitable in the past. However, it made a loss in the last twelve months, suggesting profit may be an unreliable metric at this stage. Other metrics may better explain the share price move.
我們知道Bio-Rad Laboratories過去曾經盈利。然而,過去12個月它卻虧損,這表明在這個階段盈利可能是不可靠的指標。其他指標可能更好地解釋股價波動。
With revenue flat over three years, it seems unlikely that the share price is reflecting the top line. We're not entirely sure why the share price is dropped, but it does seem likely investors have become less optimistic about the business.
營業收入在三年內保持穩定,似乎不太可能反映股價。我們不完全確定股價下降的原因,但投資者對業務的樂觀看法似乎有所減弱。
The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).
下面的圖表顯示了收益和營收隨時間的變化情況(通過單擊圖像揭示確切的值)。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240721/0-6c52c12efdfb0c4824329d10c7457fea-0-eb2a1ba8ac8df3b4cfa9bcca5b6d1b5b.png/big)
This free interactive report on Bio-Rad Laboratories' balance sheet strength is a great place to start, if you want to investigate the stock further.
如果你想進一步調查這支股票,可以在這裏開始查看Bio-Rad Laboratories資產負債表強度的免費互動報告。
A Different Perspective
不同的觀點
Investors in Bio-Rad Laboratories had a tough year, with a total loss of 28%, against a market gain of about 21%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 1.6% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. Before spending more time on Bio-Rad Laboratories it might be wise to click here to see if insiders have been buying or selling shares.
Bio-Rad Laboratories的投資者度過了艱難的一年,總損失達28%,而市場卻獲得了大約21%的收益。即使好股票的股價有時也會下跌,但我們希望在對一個公司的基本指標看到改善之前不要過於感興趣。不幸的是,去年的表現又再次證明了股東在五年內每年面臨着1.6%的總損失。一般來說,長期股價走軟可能是一個不好的跡象,儘管反向投資者可能希望研究這支股票,以尋求扭轉局面的機會。在花費更多時間研究Bio-Rad Laboratories之前,點擊這裏查看內部人士是否買賣了股票可能是明智的選擇。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.
當然,您可能在其他地方找到一家出色的企業進行投資。因此,請查看我們預計將實現盈利增長的公司的免費列表。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?對內容感到擔憂?請直接與我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋?對內容感到擔憂?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。